Kumar R, Xu L H, Knaus E E, Wiebe L I, Tovell D R, Tyrrell D L, Allen T M
Faculty of Pharmacy and Pharmaceutical Sciences, Department of Infectious Diseases and Medical Microbiology, University of Alberta, Edmonton, Canada.
J Med Chem. 1990 Feb;33(2):717-23. doi: 10.1021/jm00164a039.
A series of new 5-(1-hydroxy-2-iodoethyl)-2'-deoxyuridine and uridine compounds (11, 16) was synthesized by the regiospecific addition of HOI to the vinyl substituent of 5-vinyl-2'-deoxyuridine (10a), 5-vinyl-2'-fluoro-2'-deoxyuridine (10b), 5-vinyluridine (10c), and (E)-5-(2-iodovinyl)-2'-deoxyuridine (4b). Treatment of the iodohydrins 11a-c with methanolic sulfuric acid afforded the corresponding 5-(1-methoxy-2-iodoethyl) derivatives (12a-c). In contrast, reaction of 5-(1-hydroxy-2-iodoethyl)-2'-deoxyuridine (11a) with sodium carbonate in methanol afforded a mixture of 5-(1-hydroxy-2-methoxyethyl)-2'-deoxyuridine (13) and 2,3-dihydro-3-hydroxy-5-(2'-deoxy-beta-D-ribofuranosyl)- furano[2,3-d]pyrimidin-6(5H)-one (14). The most active compound, 5-(1-methoxy-2-iodoethyl)-2'-deoxyuridine (12a, ID50 = 0.1 micrograms/mL), which exhibited antiviral activity (HSV-1) 100-fold higher than that of the 5-(1-hydroxy-2-iodoethyl) analogue (11a), was less active than IVDU or acyclovir (ID50 = 0.01-0.1 micrograms/mL range). The C-5 substituent in the 2'-deoxyuridine series was a determinant of cytotoxic activity, as determined in the in vitro L1210 screen, where the relative activity order was CH(OH)CHI2 (16) greater than CH(OMe)CH2I (12a) greater than CH(OH)CH2I (11a) congruent to CH(OH)CH2OMe (13). The 2'-substituent was also a determinant of cytotoxic activity in the 5-(1-hydroxy-2-iodoethyl) (11a-c) and 5-(1-methoxy-2-iodoethyl) series of compounds, where the relative activity profile was 2'-deoxyuridine greater than 2'-fluoro-2'-deoxyuridine greater than uridine (11a greater than 11b greater than or equal to 11c; 12a greater than 12b greater than 12c). The most active cytotoxic agent (16), possessing a 5-(1-hydroxy-2,2-diiodoethyl) substituent (ED50 = 0.77 micrograms/mL), exhibited an activity approaching that of melphalan (ED50 = 0.15 micrograms/mL). All compounds tested, except for 13 and 14, exhibited high affinity (Ki = 0.035-0.22 mM range relative to deoxyuridine, Ki = 0.125) for the murine NBMPR-sensitive erythrocyte nucleoside transport system, suggesting that these iodohydrins are good permeants of cell membranes.
通过将HOI区域特异性加成到5-乙烯基-2'-脱氧尿苷(10a)、5-乙烯基-2'-氟-2'-脱氧尿苷(10b)、5-乙烯基尿苷(10c)和(E)-5-(2-碘乙烯基)-2'-脱氧尿苷(4b)的乙烯基取代基上,合成了一系列新的5-(1-羟基-2-碘乙基)-2'-脱氧尿苷和尿苷化合物(11、16)。用甲醇硫酸处理碘醇11a - c得到相应的5-(1-甲氧基-2-碘乙基)衍生物(12a - c)。相反,5-(1-羟基-2-碘乙基)-2'-脱氧尿苷(11a)与碳酸钠在甲醇中反应得到5-(1-羟基-2-甲氧基乙基)-2'-脱氧尿苷(13)和2,3-二氢-3-羟基-5-(2'-脱氧-β-D-呋喃核糖基)-呋喃并[2,3-d]嘧啶-6(5H)-酮(14)的混合物。活性最高的化合物5-(1-甲氧基-2-碘乙基)-2'-脱氧尿苷(12a,ID50 = 0.1微克/毫升)表现出抗病毒活性(HSV-1),比5-(1-羟基-2-碘乙基)类似物(11a)高100倍,但活性低于碘苷或阿昔洛韦(ID50在0.01 - 0.1微克/毫升范围内)。在体外L1210筛选中确定,2'-脱氧尿苷系列中的C-5取代基是细胞毒性活性的决定因素,其相对活性顺序为CH(OH)CHI2(16)大于CH(OMe)CH2I(12a)大于CH(OH)CH2I(11a)等同于CH(OH)CH2OMe(13)。2'-取代基也是5-(1-羟基-2-碘乙基)(11a - c)和5-(1-甲氧基-2-碘乙基)系列化合物中细胞毒性活性的决定因素,其相对活性分布为2'-脱氧尿苷大于2'-氟-2'-脱氧尿苷大于尿苷(11a大于11b大于或等于11c;12a大于12b大于12c)。活性最高的细胞毒性剂(16),具有5-(1-羟基-2,2-二碘乙基)取代基(ED50 = 0.77微克/毫升),其活性接近美法仑(ED50 = 0.15微克/毫升)。除了13和14之外,所有测试的化合物对小鼠NBMPR敏感的红细胞核苷转运系统都表现出高亲和力(相对于脱氧尿苷,Ki = 0.035 - 0.22毫摩尔范围,Ki = 0.125),这表明这些碘醇是细胞膜的良好渗透剂。